Enzo Biochem To Present At Lazard Capital Markets 9th Annual Healthcare Conference
Enzo Biochem, Inc. (NYSE: ENZ), a vertically integrated biosciences and
clinical laboratory company, announced today that Barry Weiner,
President, and David Goldberg, Vice President, Corporate Development,
Enzo Biochem, Inc. (NYSE: ENZ), a vertically integrated biosciences and clinical laboratory company, announced today that Barry Weiner, President, and David Goldberg, Vice President, Corporate Development, will be presenting at the Lazard Capital Markets 9th Annual Healthcare Conference on Tuesday, November 13, 2012 at 9:00 AM at The Pierre Hotel in New York, N.Y. Interested parties may listen to the presentation over the Internet at: http://wsw.com/webcast/lz13/enz/About Enzo Biochem Enzo Biochem, Inc., is a growth-oriented integrated life sciences and biotechnology company focused on harnessing biological process to develop research tools, diagnostics and therapeutics, and serves as a provider of test services, including exotic tests, to the medical community. Since our founding in 1976, our strategic focus has been on the development of enabling technologies in the life sciences field. Enzo Life Sciences develops, produces and markets proprietary labeling and detection products for gene sequencing, genetic analysis and immunological research, among others. Its catalog of over 30,000 products serves the molecular biology, drug discovery and pathology research markets worldwide. Enzo Clinical Labs provides laboratory services for a growing roster of physicians in the New York Metropolitan area, Pennsylvania and New Jersey. Its tests include, in addition to routine tests, capabilities for detecting molecular infection disease, molecular oncology, autoimmune disorders and genetics. Enzo Clinical Labs also provides clinical diagnostic services that allow Enzo to capitalize on its extensive advanced molecular and cytogenetic capabilities and the broader trends in predictive and personalized diagnostics. Enzo Therapeutics is a biopharmaceutical venture that has developed multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases. It has focused its efforts on developing treatment regimens for diseases and conditions for which current treatment options are ineffective, costly, and/or cause unwanted side effects. In the course of the company’s research and development activities, Enzo has also developed a substantial portfolio of intellectual property asset with patent coverage across a number of key technologies.